Abstract. The class VI intermediate filament protein, nestin is reported to be a progenitor cell marker in various tissues. In the present study, we analyzed the expression and roles of nestin in angiogenesis of pancreatic ductal adenocarcinomas, and determined whether nestin is a potential target for inhibiting tumor angiogenesis using a gene silencing strategy. Nestin expression was detected only in small vessels, whereas CD34, CD31 and factor VIII were also expressed in large-sized blood vessels in PDAC. The number of nestin-positive vessels was approximately 20% the number of CD34-positive vessels, and the average dimension of nestin-positive vessels was approximately 75% that of CD34-positive vessels. The PCNA labeling indices of nestin-positive vessels were higher than those of CD34-positive vessels and nestin-negative vessels. Reducing nestin expression by use of siRNA targeting nestin transcripts inhibited growth of the vascular endothelial cell lines, but there was no difference in cell motility. In xenograft models, administration of siRNA targeting mouse-nestin suppressed subcutaneous human pancreatic cancer cell growth in nude mice. In conclusion, nestin was expressed in small proliferating blood vessels in pancreatic cancer tissues and may be a useful marker of angiogenesis in pancreatic ductal adenocarcinoma tissues. Furthermore, nestin is a potential novel therapeutic target in pancreatic cancers to inhibit tumor angiogenesis.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with an overall 5-year survival rate of less than 5% (1) . PDAC patients that undergo resection frequently experience disease recurrence with a high incidence of lymph node or liver metastases and peritoneal dissemination, resulting in a poor clinical prognosis (2) . Tumor angiogenesis is an important factor in the proliferation, invasion, metastasis, and drug sensitivity of PDAC (3, 4) . A possible explanation of this metastatic mechanism is that the increased number of tumor vessels increases the chance that tumor cells enter into the circulation. Newly formed tumor vessels or capillaries have weak, leaky basement membranes; thus, tumor cells can penetrate these more easily than they can mature vessels (5) . Furthermore, increased numbers of vessels in tumors supply oxygen and nutrients to the tumor cells. The degree of tumor angiogenesis is associated with clinical outcome, and angiogenic properties correlate with tumor aggressiveness (3, 4) . Angiogenesis in malignant tumors, measured by microvessel density (MVD), reportedly correlates with prognosis in breast (6) , ovarian (7), esophageal (8) , gastric (9) , colorectal (10), prostate (11) , lung (12) , and malignant melanomas (13) , but it has been controversial in PDAC. The hot-spot method and the lumen method using endothelial specific antigens are reportedly useful for analyzing tumor angiogenesis (14, 15) . CD34, CD31, and factor VIII are commonly used as endothelial cell markers in tumor vessels. However, these markers identify not only newly-formed small vessels, but also pre-existing large blood vessels (16) .
Nestin is a class VI intermediate filament protein originally found in neuroepithelial stem cells and neural cells (17) . Nestin expression was up-regulated in progenitor cells in various tissues such as muscle, testis, teeth, heart, and pancreas. This upregulation was usually followed by decreased expression when the cells reached their differentiated states (18) (19) (20) . Furthermore, increased nestin expression has been reported in various tumor cells, including central nervous system tumors (21), PDACs (22) , gastrointestinal stromal tumors (23) , prostate cancers (24) , breast cancers (25) , malignant melanomas (26) , dermatofibrosarcoma protuberances (27) and thyroid tumors (28) .
Recently, nestin expression in endothelial cells that accompanied the process of angiogenesis has been reported (29) (30) (31) (32) (33) . The nestin expression was specific to proliferative endothelium, and nestin regulates the proliferation of HUVEC cells. We reported that nestin-positive vessels show higher proliferation rates than CD34-positive vessels in colorectal carcinoma (30) and nestin is strongly expressed in proliferating endothelial cells in a rat model of acute pancreatitis (34) . Furthermore, nestin was reported to be a marker of proliferating endothelial cells in brain tumor tissues (35) and prostate cancer (36) .
Nestin as a novel therapeutic target for pancreatic cancer via tumor angiogenesis
KAZUYA YAMAHATSU 1, 2 These reports indicate that nestin may be a useful marker of newly-formed blood vessels in tumor tissues. Regarding PDAC, studies focusing on angiogenesis have gradually increased in recent years. However, detailed expression patterns and the roles of nestin in vascular endothelial cells of PDAC have not been reported. In this study, we compared the number, dimension and proliferative ability of nestin-and CD34-positive blood vessels in PDAC tissues to determine the usefulness of nestin as a marker of angiogenesis in this disease. We determined the effect of small interfering RNA (siRNA) targeting nestin in vitro and in vivo to clarify whether nestin could be a novel therapeutic target of tumor angiogenesis in PDAC. Microvessel counting. Microvessels were assessed according to the international consensus report (37) . In short, slides immunostained with anti-human nestin or anti-human CD34 antibodies were scanned at magnification x100 to identify the areas with the highest number of vessels. Each image was captured using an Olympus DP71 Digital Camera system (Olympus Optical, Tokyo, Japan) attached to an Olympus AX80 microscope at magnification x200. Each magnification x200 area was 0.64 mm 2 . Counts were performed on five separate fields, and a lumen with stained epithelial cells was counted as one vessel by WinROOF version 6.1.3 (Mitani Corp., Tokyo, Japan) (38) . The number and dimension of microvessels were counted, and the median of the microvessel counts was used for analyses. 
Materials and methods

Materials
No. of nestin(+) vessels
No. of CD34(+) vessels Heterotopic and orthotopic xenografted tumors in mice. Sixweek-old male nude mice (BALB/cA Jcl-nu/nu; CLEA Japan Inc., Tokyo, Japan) were subcutaneously injected in the right flank with 1x10 6 PANC-1 cells/mouse (N=8). Four weeks later, the mice were euthanized and the tumors were excised. Furthermore, to evaluate the orthotopic xenografted tumors of human pancreatic cancer cells, we used NOD/Shi-scid, IL-2γ null (NOG; Central Institute for Experimental Animals, Kanagawa, Japan) mice (39) . We injected 1x10 5 PANC-1 cells into the spleen of NOG mice (N=12), and then splenectomy was performed after 1 min. Eight weeks later, 2 mice exhibited abdominal tumors in the area adjacent to the pancreas, and the pancreatic tumors were excised. Portions of the subcutaneous and pancreatic tumors were fixed in 4% paraformaldehyde for routine histopathological processing (40) . Animal experiments were carried out according to the institutional animal care guidelines of the Nippon Medical School Animal Ethics Committee.
Transfection of small interfering RNA (siRNA).
Pre-designed siRNA targeting mouse-nestin (siRNA ID: s70481), targeting human-nestin (s21143), and negative control siRNA (silencer select negative control no. 1) were obtained from Applied Biosystems, Inc. Sense and anti-sense mouse-nestin siRNA sequences were 5'-GACUGGUAGAGAAAGAGGA-3' and 5'-UCCUC UUUCUCUACCAGUC-3', respectively. Sense and anti-sense human nestin siRNA sequences were 5'-GACUGGUAGAG AAAGAGGA-3' and 5'-UCCUCUUUCUCUACCAGUC-3', respectively. Cells were transfected with the siRNAs in serumfree DMEM medium using TransIT-si-QUEST transfection reagent. In short, each siRNA stock solution and TransIT-si-QUEST (2.5 µl/well) were mixed in serum-free DMEM medium. After immediate mixing and incubation at room temperature (RT) for 15 min, this siRNA-lipid complex was added to cultured cells (2x10 5 cells/6-well plate). The cells were incubated for 24 h at 33˚C, then the medium was replaced with fresh DMEM containing 10% FBS. The treated cells were cultured for 48 h then collected for analyses. Prior to this examination, we tried to transfect the siRNAs at a concentration of 2.5-20 nM, and the appropriate concentration of siRNAs was determined as 5 nM by quantitative reverse transcription-PCR (qRT-PCR). We tried two kinds of siRNAs for each to target mouse or human nestin to inhibit nestin expression (s70481 and s70479 for mouse; s21143 and s21141 for human), and stronger inhibitors of nestin expression (s70481 and s21143) were used in the present study.
qRT-PCR. Total RNA was extracted from cells using a FastPure RNA kit. One microgram of total RNA per sample was used for RT with a High-Capacity cDNA Reverse Transcription kit following the manufacturer's protocol. qRT-PCR for mousenestin (Mm03053244_s1), human-nestin (Hs00707120_s1) and 18S rRNA (Hs99999901_s1) was performed using the StepOnePlus PCR system (Applied Biosystems, Inc.) with specific primers and a TaqMan probe. PCR was carried out in 20-µl reaction mixtures containing 10 µl of 2X TaqMan Gene Expression Master Mix, 2 µl of template cDNA, and 1 µl of TaqMan Gene Expression Assays. Cycling conditions were as follows: 20 sec at 95˚C then 40 cycles for 1 sec at 95˚C followed by 20 sec at 60˚C. qRT-PCR results were expressed as target/18S rRNA as an internal standard concentration ratio. Gene expression levels were always measured in triplicate.
Immunofluorescence analysis. TKD2 cells (1x10 5 cells) were plated on 35-mm glass-bottomed dishes and treated with siRNAs as described above. After 72 h of siRNA treatment, the cells were fixed in 4% paraformaldehyde solution for 15 min at RT. The fixed cells were treated with 50 mM glycine for 5 min, 0.1% Triton X-100 for 5 min, and 10% rabbit serum for 30 min at RT. Next, the cells were incubated with a goat anti-mouse nestin antibody (dilution, 1:50) or a mouse anti-human nestin antibody (dilution, 1:50) overnight at 4˚C, followed by a FITClabeled anti-goat or Alexa 488-labeled donkey anti-mouse IgG antibody IgG antibody (dilution, 1:1000). Then the dishes were mounted with Vectashield H-1200 containing DAPI. The nestin protein expression of cells was observed under a Digital Eclipse C1 TE2000-E microscope (Nikon Insteck Co., Ltd., Kanagawa, Japan) with a blue diode (excitation, 405 nm; emission, 450/35 nm) and an argon laser (excitation, 488 nm; emission, 515/30 nm). Fluorescence images were acquired and analyzed using confocal microscope Digital Eclipse C1 control software EZ-C1 (Nikon Insteck Co., Ltd.). The confocal settings including laser power and detector sensitivity were unchanged during the acquisition of all images.
Cell proliferation assay. To examine the growth rates, a nonradioactive cell proliferation assay was performed. TKD2 cells (5x10 3 cells/well) were seeded in 96-well plates, and incubated at 33˚C in a humidified 5% CO 2 atmosphere for 24, 48, 72, 96 and 120 h. Cells were then incubated with WST-8 cell counting reagent for 4 h at 33˚C and the optical density at 450 nm of the solution in the plate was measured using an ELISA plate reader (Bio-Rad Laboratory, Hercules, CA). All assays were performed in triplicate.
Next, we performed cell proliferation assays after administration of mouse or human-nestin siRNA. siRNA was administered to cell suspension and then cells (1x10 4 cells/well) were plated in 6-well plate. After 96 h, the cell number was counted using a C-Reader (Digital Bio Technology Co., Ltd., Kyungki-do, Korea). All assays were performed in triplicate.
Single-cell movement assay. To confirm the effects of nestin on cell migration, a single-cell movement assay was performed next as described previously (41) . Briefly, TKD2 cells (5,000 cells/ well) were seeded onto 4-well glass bottom dishes and grown for 48 h. Cell movement was then monitored for 24 h by a Digital Eclipse TE-200-E motorized inverted microscope which photographed the cells every 5 min. The total distance of individual cells covered within 24 h was determined using the MetaMorph software 7.6 (Universal Image Corp., Ltd., Buckinghamshire, UK). Images from four areas in each well at magnification x100 were taken, and the movement all cells in the fields was analyzed. Approximately 100 cells in each well were analyzed for single-cell movement.
In vivo administration of siRNA targeting nestin. To examine the effect of reduced nestin expression on in vivo tumorigenicity, KLM-1 cells/animal (1x10 6 ) were injected subcutaneously into 6-week-old male nude mice. KLM-1 cells exhibited relatively low expression of human nestin; therefore, we used KLM-1 cells to evaluate the effect of siRNA targeting mouse nestin in mouse vascular endothelial cells to avoid the possibility of cross-reaction of the mouse nestin siRNA to human nestin in vivo. Seven days after injection of KLM-1 cells, tumor cell-bearing mice were randomly divided into 3 groups (mousenestin siRNA, negative siRNA, and phosphate buffered saline (PBS) treated group. Each group contained three animals. To improve the efficiency of siRNA transfection in vivo, we used AteloGene (42) . The siRNA and AteloGene mixture was injected directly into the tumor (1 nM siRNA with 100 µl of AteloGene). The injections were performed 3 times weekly. The quantity of siRNA and AteloGene, and the intervals and method of injection were performed according to the manufacturer's protocol. The animals were monitored for tumor formation then sacrificed 23 days after injection. Tumor volume was calculated using the following formula: volume = a x b 2 x 0.5, where a is the longest diameter and b is the shortest one. The tumors were removed, fixed in 20% neutral-buffered formalin, and embedded in paraffin. The sections (3.5 µm) were used for immunohistochemical staining of mouse-nestin.
Statistical analyses.
To analyze the correlations between clinicopathological factors and nestin-positive or CD34-positive endothelial cells, the χ 2 test was used. The unpaired t-test or Mann Whitney U test was used to analyze the correlation between two groups. Disease-free survival curves were computed according to the Kaplan-Meier method; differences in survival were computed using the log-rank test. A P<0.05 was considered significant. Computations were performed using the StatView J version 5.0 (SAS Institute, Inc., Cary, NC) software package.
Results
Immunohistochemical analyses of nestin and CD34 in normal and non-cancer human pancreatic tissues.
We examined the localization of nestin and CD34 in non-cancer pancreatic tissue that were obtained from tissue sections of the heterotopic spleen of the pancreas and commercially-obtained normal pancreatic tissue. Nestin was not or rarely detected in vascular endothelial cells, whereas CD34 was detected in capillary endothelial cells in endocrine and exocrine pancreatic tissues (Fig. 1, arrows) .
Immunohistochemical analysis of nestin in human PDAC tissues.
Several vascular endothelial cells showed nestin expression in the areas near PDAC cells ( Fig. 2A, arrowheads) . To confirm the expression of nestin in vascular endothelial cells, immunostaining of common vascular endothelial markers, CD34, CD31 and factor VIII was performed in serial tissue sections ( Fig. 2A) . Nestin-positive vessels included only part of the CD34 -, CD31 , and factor VIII-positive vessels. Relatively small-sized vessels expressed nestin ( Fig. 2A, arrowheads) , whereas large-sized vessels did not express nestin ( Fig. 2A, arrows) . CD34, CD31 and factor VIII were expressed in both small-and large-sized blood vessels (Fig. 2A, arrowheads and arrows) . α-SMApositive smooth muscle cells ( Fig. 2A, arrows) and elastic lamina ( Fig. 2A, arrows) were located only in large-sized blood vessels. These results suggest that in the areas adjacent to PDAC cells, nestin is specifically expressed in small-sized blood vessels that do not possess thick walls with smooth muscle and elastic lamina.
Next, we determined whether nestin was expressed in lymphatic vessels. Nestin-positive vessels did not express D2-40 in human PDAC tissues (Fig. 2B, black arrowheads) . By contrast, D2-40-positive lymph vessels did not express nestin (Fig. 2B,  arrows) . Both nestin and D2-40 were expressed in nerve fibers (Fig. 2B, white arrowheads) . Staining patterns of LYVE-1 and VEGFR3 in PDAC tissues were similar to those of D2-40 (data not shown).
Immunohistochemical analyses of PCNA in nestin-or CD34-positive vessels in human PDAC tissues. We performed immunohistochemical analyses of PCNAs to compare the cell proliferative activity with nestin-positive or CD34-positive blood vessels in PDAC tissues. PCNA immunoreactivity was detected in the nuclei of most PDAC cells and some vascular endothelial cells. In serial tissue sections, nestin-positive vascular endothelial cells nearby PDAC cells co-expressed the proliferation marker, PCNA in their nucleus (Fig. 3A, arrowheads) . We counted the number of PCNA-positive cells in nestin-and CD34-positive vascular endothelial cells (Fig. 3B ), but there was no statistically significant difference in PCNA-positive cells between the two cell types. Next, we determined the PCNAlabeling indices of nestin-positive and nestin-negative vessels. Nestin-positive vessels showed higher PCNA labeling indices than nestin-negative vessels (Fig. 3C, P<0 .05).
Analyses of the numbers and dimensions of nestin or CD34-positive vessels using image analysis software.
Nestin was also detected in a small number of spindle cells adjacent to PDAC cells, and the cells were stained with α-SMA or S-100 in serial tissue sections (data not shown). Therefore, the number and dimensions of lumen-forming nestin-positive vessels or CD34-positive vessels (Fig. 4A, arrows) were analyzed using the image analysis software WinROOF. Green areas in Fig. 4A indicate nestin-or CD34-positive vessels, respectively. The number of nestin-and CD34-positive vessels per field was 24.3±8.9 (3.0-77.0) and 120.8±2.6 (29.0-351.0), respectively. The number of nestin-positive vessels was ~20% the number of CD34-positive vessels (Fig. 4B, P<0 .0001). The average dimension of nestin-and CD34-positive vessels was 200.8±20.1 (12.0-708.3) and 270.4±33.6 µm 2 (97.1-1555.2 µm 2 ), respectively. The average dimension of nestin-positive vessels was ~75% that of CD34-positive vessels (Fig. 4C, P<0 , respectively. The total dimension of nestin-positive vessels was ~15% that of CD34-positive vessels (Fig. 4D, P<0 .0001). These findings using image analysis software showed that nestin was expressed in a smaller number of blood vessels and in smaller-sized blood vessels than CD34.
Correlations between clinicopathological findings and nestin-or CD34-positive vessels. We divided PDAC cases into two groups by the median value of nestin-or CD34-positive vascular vessels. There were no statistically significant differences in histology, stage, vascular invasion of lymph duct invasion between groups with high and low numbers of nestin-or CD34-positive vessels (Table I ). There were also no significant differences between nestin-or CD34-positive vessels and survival curves Figure 1 . Immunohistochemical analyses of nestin and CD34 in normal human pancreatic tissues. In normal pancreatic tissues, nestin showed weak or absent expression, whereas CD34 was detected in capillary endothelial cells (arrows). Arrows, capillary endothelial cells; arrowheads, pancreatic ducts; asterisks, islets; scale bar, 100 µm. ( Fig. 4E and F) , recurrence-free survival rate, or liver metastasisfree survival rate (data not shown).
Immunohistochemical analyses of nestin and CD34 in mice with xenografted human pancreatic cancers. We examined the nestin-and CD34-immunoreactivities in tumor blood vessels using mice with xenografted human PDAC cells. In subcutaneously-implanted PANC-1 cells, nestin-positive vascular endothelial cells were detected in small-sized vessels (Fig. 5A,  arrowheads) but not in large-sized ones (arrows). In contrast, CD34 was detected in both small-and large-sized blood vessels (Fig. 5A, arrowheads and arrows, respectively) . Eight weeks after the intrasplenic injection of PANC-1 cells, the cells formed intra-abdominal tumors very close to pancreatic tissues (Fig. 5B,  asterisks) . Nestin was detected in small-sized blood vessels (Fig. 5B, arrowheads) but not large-sized ones (arrows). On the other hand, CD34 was detected in both small-and large-sized blood vessels (Fig. 5B, arrows and arrowheads) . By counting the 5 hot-spot fields nearby PDAC cells at magnification x200 fewer nestin-positive vessels than CD34-positive vessels were seen in these areas (Fig. 5C, P<0 .05). These results suggest that nestin is specifically expressed in newly-formed tumor vessels in mouse xenograft models. Fig. 6A ). Immunocytochemically, nestin protein levels were also decreased in siNestin cells compared with siNegative cells (Fig. 6B) . Cell morphology was not altered by treatment with nestin siRNA or negative siRNA.
Effects of reduced nestin expression levels on cell growth and
We examined whether reduced nestin expression affects the growth and migration activities of vascular endothelial cells. In TKD2 cells, the growth rate of siNestin cells was markedly inhibited compared with that of siNegative cells and untreated cells, and the difference was statistically significant at 96 and 120 h (Fig. 6C, P<0 .05). Next, we confirmed the growthinhibitory effects of nestin siRNA in TKD2 and HUVEC-2 cells using a cell-counting method. Nestin siRNA transfection in the vascular endothelial cells induced a significant decrease in cell number after 96 h ( * P<0.05, Fig. 6D ). To determine cell migration ability, single-cell movement was monitored by time-lapse microscopy; however, no significant difference in TKD2 cell motility between siNestin cells and siNegative cells was observed ( Fig. 6E and F) .
Effects of reduced nestin expression levels on tumor growth in nude mice. In mouse TKD2 endothelial cells, siNestin at a concentration of 5 and 10 nM markedly decreased nestin mRNA expression (Fig. 7A) . In contrast, negative siRNA at the concentration of 10 nM did not decrease nestin mRNA expression in TKD2 cells. In human KLM-1 PDAC cells, which express human nestin mRNA, siRNA targeting mouse-nestin did not affect human nestin expression levels (Fig. 7B) . Next, we examined whether siNestin could inhibit human PDAC cell growth in vivo via anti-angiogenic effects on mouse tumor vessels. To improve the efficiency of in vivo transfection of siRNAs, we injected siRNA into subcutaneous tumors with AteloGene, according to the manufacturer's protocol. siNestin significantly inhibited tumor growth in vivo compared with the siNegative and PBS-treated groups (Fig. 7C and D, P<0 .05). To confirm the silencing effect of siNestin at the protein level, we performed immunostaining of nestin in siRNA-treated mouse tumors. Immunohistochemically, many nestin-positive vessels were detected in subcutaneous tumors in the siNegative group (Fig. 7E, arrows) , whereas only a few nestin-positive vessels were detected in the areas adjacent to PDAC cells in the siNestin group (arrowheads). The number of nestin-positive vessels were significantly decreased in siNestin group when compared with the siNegative group (Fig. 7F, P<0.05 ). 
Discussion
CD34, CD31 and factor VIII are commonly used as vascular endothelial markers to determine MVD; however, which marker is best suited to analyze MVD has been controversial (43) (44) (45) . To determine MVD in PDAC tissues, CD34 is more commonly used than CD31 or factor VIII (14, 15, 46, 47) . Therefore, we compared the expression of nestin and CD34 in newly-formed blood vessels in PDAC tissues. The expression of nestin was specific to small, highly proliferative blood vessels in PDAC tissues, whereas CD34 was expressed in all-sized vessels. Previously, some endothelial cells and lymphangioendothelial cells were reported to express both lymphangioendothelial and vascular endothelial cell markers. However, nestin-positive endothelial cells in PDAC did not express all of the lymphangioendothelial markers examined. These findings suggest that nestin expression is specifically expressed in proliferating vascular endothelial cells, consistent with a previous report (48) .
We compared the relationship between MVD of nestinpositive vessels and clinicopathological factors, but there was no statistically significant difference. The MVD of CD34-positive vessels also showed no relationship with clinicopathological factors. Several reports show that the MVD in PDAC determined with the hot-spot method using factor VIII or CD34 correlated with poor prognosis (49) (50) (51) . In contrast, several reports showed that MVD determined with the hot-spot method using factor VIII or CD34 does not correlate with prognosis or liver metastasis (52, 53) and that the lumen method using factor VIII is superior to the hot-spot method (14, 15) . Furthermore, it has been shown that a close relationship exists between intratumoral MVD and prognosis using CD34 in 104 PDAC patients (51) . These data indicate that reference methods for measuring tumor angiogenesis are still controversial. In the present study, nestin was expressed in smaller-sized and highly-proliferative endothelial cells rather than with other commonly used angiogenic markers; thus, large-scale clinical research might be needed to clarify the effectiveness of MVD using nestin-positive vessels in PDAC.
Reducing nestin expression in endothelial cells with nestin siRNA inhibited proliferation; therefore, nestin is important for the growth of the vascular endothelium, and might be a therapeutic target for inhibiting tumor angiogenesis. Nestin contributes to the disassembly of vimentin during mitosis (54) inactivates the proapoptotic cyclin-dependent kinase 5 (55) and modulates mitosis-associated cytoplasmic reorganization during mitosis after becoming phosphorylated on Thr 316 by cdc2 kinase (56) . Down-regulating nestin expression in neural progenitor cells inhibited cyclin D1/E expression (57) . The nestin gene has four exons and three introns. Neural cell-specific expression is reported to be regulated by the second intron, whereas nestin expression in tumor endothelium is enhanced by the first intron. These observations suggest that nestin in tumor endothelium is not only a structural protein, but also closely correlated with endothelial cell proliferation (48) .
The effectiveness of anti-angiogenic agents for cancer treatment has been widely reported. The present study indicates that nestin inhibits the growth of mouse vascular endothelial cells in vitro and in vivo. In addition, nestin inhibits the growth of human primary cultured vascular endothelial cells in vitro. Thus, nestin may serve as a novel therapeutic target in PDAC angiogenesis similar to VEGFR inhibitors (58) . Furthermore, expression of nestin in PDAC cells was detected in approximately 30% of PDAC cases (22) . Recently, we have reported that reduced expression level of nestin in PDAC cells attenuated migration, invasion and metastasis (59) . Therefore, nestin may become a new molecular target for both PDAC cells and tumor angiogenesis for nestin-expressing PDAC cases.
In conclusion, nestin was expressed in small growing blood vessels in pancreatic cancer tissues, and may be a useful marker of angiogenesis in PDAC tissues. Furthermore, nestin may be a novel therapeutic target in pancreatic cancers.
